Drawing for SANTHERA

USPTO serial 77320647

SANTHERA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BROWNE, DAYNA
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SANTHERA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Patrick J. Concannon

PATRICK J. CONCANNON EDWARDS ANDELL PALMER & DODGE LLP111 HUNTINGTON AVENUEBOSTON, MA 02199UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular and metabolic system including diabetes, the respiratory system, musculoskeletal and inflammatory disorders, or for use in dermatology, oncology, hematology, ophthalmology, in transplantation; but not for use in the fields of onlcology or rheumatoid arthritis; pharmaceutical preparations for the treatment of bone, endocrinological, circulatory, hormonal and rheumatic disorders; but not for use in the fields of onlcology or rheumatoid arthritis; pharmaceutical preparations for use in gastro-enterology, for the prevention and treatment of ocular disorders; anti-infectives, anti-bacterials, antivirals, antibiotics, anti-fungals, vaccines, but not for use in the fields of onlcology or rheumatoid arthritis; pharmaceutical preparations for diagnostic purposes, namely, diagnostic preparations for medical purposes; but not for use in the fields of onlcology or rheumatoid arthritis; pharmaceutical preparations for the treatment of central nervous system-related conditions, neurological and muscular diseases, neuro-muscular diseases, muscular dystrophies, ataxias, amyotrophia, atrophy, ophthalmological diseases, muscle wasting, cardiomyopathies, optic nerve degradation, neurological indications, memory loss, Lou Gebrig's disease, Parkinson's disease, Huntington's disease, spinal muscular atrophies, polyneurophaties, fibromyalgia, mononeuropathies, neuromuscular junction disorders, myotonia and myopathies; but not for use in the fields of onlcology or rheumatoid arthritis; reagents for medical use; biological preparations for medical purposes but not for use in the fields of onlcology or rheumatoid arthritis; diagnostic agents, preparations and substances for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 9, 2013MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 9, 2013ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 9, 2013DOCKASSIGNED TO EXAMINER—
May 25, 2013EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 24, 2013EX5GSOU EXTENSION 5 GRANTED—
May 24, 2013AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 29, 2013EXT5SOU EXTENSION 5 FILED—
Apr 29, 2013EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 31, 2012EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 30, 2012EX4GSOU EXTENSION 4 GRANTED—
Oct 25, 2012EXT4SOU EXTENSION 4 FILED—
Oct 25, 2012EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 3, 2012EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 2, 2012EX3GSOU EXTENSION 3 GRANTED—
Apr 25, 2012EXT3SOU EXTENSION 3 FILED—
Apr 25, 2012EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 3, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 2, 2011EX2GSOU EXTENSION 2 GRANTED—
Nov 1, 2011AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 31, 2011EXT2SOU EXTENSION 2 FILED—
Oct 31, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 14, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 12, 2011EX1GSOU EXTENSION 1 GRANTED—
Apr 12, 2011EXT1SOU EXTENSION 1 FILED—
Apr 12, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 2, 2010NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 17, 2010MAILPAPER RECEIVED—
Sep 17, 2010TMBNTTAB RELEASE CASE TO TRADEMARKS—
Sep 17, 2010OP.TOPPOSITION TERMINATED NO. 999999—
Sep 17, 2010OP.DOPPOSITION DISMISSED NO. 999999—
May 19, 2010ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 19, 2010REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 13, 2010MAILPAPER RECEIVED—
Mar 30, 2009OP.IOPPOSITION INSTITUTED NO. 999999—
Oct 30, 2008ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Sep 30, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 10, 2008NPUBNOTICE OF PUBLICATION—
Aug 26, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 22, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 22, 2008ACECAMENDMENT FROM APPLICANT ENTERED—
Aug 22, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 12, 2008MAILPAPER RECEIVED—
Feb 16, 2008CEPECOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED—
Feb 15, 2008ALIEASSIGNED TO LIE—
Feb 15, 2008GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Feb 15, 2008GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Feb 15, 2008CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Feb 14, 2008DOCKASSIGNED TO EXAMINER—
Nov 7, 2007NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance